Dangas GD, Tijssen JGP, Wohrle J, et al. - In this study, researchers explored how the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR). A sum of 1,644 individuals were included in this study. Individuals were assigned randomly without a confirmed indication for oral anticoagulation after successful TAVR to receive rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months) (rivaroxaban group) or aspirin at a dose of 75 to 100 mg daily (with clopidogrel at a dose of 75 mg daily for the first 3 months) (antiplatelet group). The composite of death or thromboembolic events were the primary efficacy outcome. Although, major, disabling, or life-threatening bleeding were primary safety outcome. In comparison with the antiplatelet-based strategy, a treatment strategy involving rivaroxaban at a dose of 10 mg daily was correlated with a higher risk of death or thromboembolic complications and a higher risk of bleeding in individuals without an established indication for oral anticoagulation after successful TAVR.